Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 1/2010

Open Access 01-01-2010 | Original Article

Updated fracture incidence rates for the US version of FRAX®

Authors: B. Ettinger, D. M. Black, B. Dawson-Hughes, A. R. Pressman, L. J. Melton III

Published in: Osteoporosis International | Issue 1/2010

Login to get access

Abstract

Summary

On the basis of updated fracture and mortality data, we recommend that the base population values used in the US version of FRAX® be revised. The impact of suggested changes is likely to be a lowering of 10-year fracture probabilities.

Introduction

Evaluation of results produced by the US version of FRAX® indicates that this tool overestimates the likelihood of major osteoporotic fracture. In an attempt to correct this, we updated underlying fracture and mortality rates for the model.

Methods

We used US hospital discharge data from 2006 to calculate annual age- and sex-specific hip fracture rates and age-specific ratios to estimate clinical vertebral fracture rates. To estimate the incidence of any one of four major osteoporotic fractures, we first summed these newly derived hip and vertebral fracture estimates with Olmsted County, MN, wrist and upper humerus fracture rates, and then applied 10–20% discounts for overlap.

Results

Compared with rates used in the current FRAX® tool, 2006 hip fracture rates are about 16% lower, with greatest reductions observed among those below age 65 years; major osteoporotic fracture rates are about one quarter lower, with similar reductions across all ages.

Conclusions

We recommend revising the US-FRAX by updating current base population values for hip fracture and major osteoporotic fracture. The impact of these revisions on FRAX® is likely to be lowering of 10-year fracture probabilities, but more precise estimates of the impact of these changes will be available after these new rates are incorporated into the FRAX® tool.
Literature
1.
USDHHS (2004) Bone health and osteoporosis: a report of the surgeon general. US Department of Health and Human Services, Rockville
2.
Kanis JA, Melton LJ III, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedCrossRef
3.
NOF (2002) America’s bone health: the state of osteoporosis and low bone mass in our nation. National Osteoporosis Foundation, Washington
4.
Burge R, Dawson-Hughes B, Solomon DH et al (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475CrossRefPubMed
5.
USDHHS (2004) Chapter 1. A public health approach to promote bone health. Bone health and osteoporosis: a report of the surgeon general. US Department of Health and Human Services, Rockville, pp 3–15
6.
Nieves JW, Barrett-Connor E, Siris ES et al (2008) Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporos Int 19:673–679CrossRefPubMed
7.
Rizzoli R, Boonen S, Brandi ML et al (2008) The role of calcium and vitamin D in the management of osteoporosis. Bone 42:246–249CrossRefPubMed
8.
Bolland MJ, Barber PA, Doughty RN et al (2008) Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 336:262–266CrossRefPubMed
9.
MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213PubMed
10.
Biswas PN, Wilton LV, Shakir SA (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507–514CrossRefPubMed
11.
12.
Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491CrossRefPubMed
13.
Stone KL, Seeley DG, Lui LY et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:1947–1954CrossRefPubMed
14.
Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202CrossRefPubMed
15.
Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112CrossRefPubMed
16.
Cranney A, Jamal SA, Tsang JF et al (2007) Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177:575–580PubMed
17.
De Laet C, Oden A, Johansson H et al (2005) The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16:313–318CrossRefPubMed
18.
Kanis JA; on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. Printed by the University of Sheffield
19.
Dawson-Hughes B, Lindsay R, Khosla S et al (2008) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC
20.
Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed
21.
Melton LJ III, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29–37CrossRefPubMed
22.
Melton LJ III, Kearns AE, Atkinson EJ et al (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687–694CrossRefPubMed
23.
Zingmond DS, Melton LJ III, Silverman SL (2004) Increasing hip fracture incidence in California Hispanics, 1983 to 2000. Osteoporos Int 15:603–610CrossRefPubMed
24.
Hiebert R, Aharonoff GB, Capla EL et al (2005) Temporal and geographic variation in hip fracture rates for people aged 65 or older, New York State, 1985–1996. Am J Orthop 34:252–255PubMed
25.
Gehlbach SH, Avrunin JS, Puleo E (2007) Trends in hospital care for hip fractures. Osteoporos Int 18:585–591CrossRefPubMed
26.
Melton LJ III, Therneau TM, Larson DR (1998) Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int 8:68–74CrossRefPubMed
27.
Dawson-Hughes B, Tosteson AN, Melton LJ III et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458CrossRefPubMed
28.
Kung H-C, Hoyert DL, Xu J et al (2007) Deaths: preliminary data for 2005. National Center for Health Statistics Health E-Stats, September
29.
Delmas PD, Marin F, Marcus R et al (2007) Beyond hip: importance of other nonspinal fractures. Am J Med 120:381–387CrossRefPubMed
30.
Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674CrossRefPubMed
31.
Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefPubMed
32.
Melton LJ III, Atkinson EJ, Cooper C et al (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221CrossRefPubMed
33.
Gallacher SJ, Gallagher AP, McQuillian C et al (2007) The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int 18:185–192CrossRefPubMed
34.
Melton LJ III, Kallmes DF (2006) Epidemiology of vertebral fractures: implications for vertebral augmentation. Acad Radiol 13:538–545CrossRefPubMed
35.
Tosteson AN, Melton LJ III, Dawson-Hughes B et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMed
36.
Donaldson MG, Cawthon PM, Lui LY et al (2009) Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res 24:675–680
Metadata
Title
Updated fracture incidence rates for the US version of FRAX®
Authors
B. Ettinger
D. M. Black
B. Dawson-Hughes
A. R. Pressman
L. J. Melton III
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 1/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-009-1032-9

Other articles of this Issue 1/2010

Osteoporosis International 1/2010 Go to the issue

Review

The effects of exercise and physical activity participation on bone mass and geometry in postmenopausal women: a systematic review of pQCT studies

Original Article

Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women

Original Article

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

Short Communication

Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review

Original Article

The potential impact of new National Osteoporosis Foundation guidance on treatment patterns

Original Article

Validation of the IOF quality of life questionnaire for patients with wrist fracture